This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by New, M. I. Articles by Wilson, R. C. Search for Related Content PubMed PubMed Citation Articles by New, M. I. Articles by Wilson, R. C.

EXTENSIVE PERSONAL EXPERIENCE: Prenatal Diagnosis for Congenital Adrenal Hyperplasia in 532 Pregnancies

Pediatric Endocrinology, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York 10021

Address all correspondence and requests for reprints to: Maria I. New, M.D., Department of Pediatrics, Division of Pediatric Endocrinology, New York Hospital-Cornell Medical Center, 525 East 68th Street, Room M-622, New York, New York 10021.

Abstract

Congenital adrenal hyperplasia (CAH) refers to a family of monogenic inherited disorders of adrenal steroidogenesis most often caused by enzyme 21-hydroxylase deficiency (21-OHD). In the classic forms of CAH (simple virilizing and salt wasting), androgen excess causes external genital ambiguity in newborn females and progressive postnatal virilization in males and females. Prenatal treatment of CAH with dexamethasone has been successfully used for over a decade.

This article serves as an update on 532 pregnancies prenatally diagnosed using amniocentesis or chorionic villus sampling between 1978 and 2001 at New York Presbyterian Hospital-Weill Medical College of Cornell University. Of the 532 pregnancies, 281 were prenatally treated for CAH due to the risk of 21-hydroxylase deficiency. Follow-up telephone interviews with mothers, genetic counselors, endocrinologists, pediatricians, and obstetricians were performed in all cases.

Of the pregnancies evaluated, 116 babies were affected with classic 21-OHD. Of these, 61 were female, 49 of whom were treated prenatally with dexamethasone. Dexamethasone administered at or before 9 wk gestation (in proper doses) was effective in reducing virilization. There were no statistical differences in the symptoms during pregnancy between mothers treated with dexamethasone and those not treated with dexamethasone, except for weight gain, edema, and striae, which were greater in the treated group. No significant or enduring side-effects were noted in the fetuses, indicating that dexamethasone treatment is safe. Prenatally treated newborns did not differ in weight from untreated, unaffected newborns. Based on our experience, prenatal diagnosis and proper prenatal treatment of 21-OHD are effective in significantly reducing or eliminating virilization in the newborn female. This spares the affected female the consequences of genital ambiguity, genital surgery, and possible sex misassignment.

This article has been cited by other articles:

				T. Hirvikoski, A. Nordenstrom, T. Lindholm, F. Lindblad, E M. Ritzen, and S. Lajic Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? Eur. J. Endocrinol., September 1, 2008; 159(3): 309 - 316. [Abstract] [Full Text] [PDF]

				D. P. Merke Approach to the Adult with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 653 - 660. [Abstract] [Full Text] [PDF]

				T. Hirvikoski, A. Nordenstrom, T. Lindholm, F. Lindblad, E. M. Ritzen, A. Wedell, and S. Lajic Cognitive Functions in Children at Risk for Congenital Adrenal Hyperplasia Treated Prenatally with Dexamethasone J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 542 - 548. [Abstract] [Full Text] [PDF]

				D. I. Shulman, M. R. Palmert, S. F. Kemp, and for the Lawson Wilkins Drug and Therapeutics Commi Adrenal Insufficiency: Still a Cause of Morbidity and Death in Childhood Pediatrics, February 1, 2007; 119(2): e484 - e494. [Abstract] [Full Text] [PDF]

				D. Keen-Kim, J. B. Redman, R. U. Alanes, M. M. Eachus, R. C. Wilson, M. I. New, J. M. Nakamoto, and R. G. Fenwick Validation and Clinical Application of a Locus-Specific Polymerase Chain Reaction- and Minisequencing-Based Assay for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) J. Mol. Diagn., May 1, 2005; 7(2): 236 - 246. [Abstract] [Full Text] [PDF]

				M. G. Forest Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency Hum. Reprod. Update, November 1, 2004; 10(6): 469 - 485. [Abstract] [Full Text] [PDF]

				H. F. L. Meyer-Bahlburg, C. Dolezal, S. W. Baker, A. D. Carlson, J. S. Obeid, and M. I. New Cognitive and Motor Development of Children with and without Congenital Adrenal Hyperplasia after Early-Prenatal Dexamethasone J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 610 - 614. [Abstract] [Full Text] [PDF]

				M. Manikkam, E. J. Crespi, D. D. Doop, C. Herkimer, J. S. Lee, S. Yu, M. B. Brown, D. L. Foster, and V. Padmanabhan Fetal Programming: Prenatal Testosterone Excess Leads to Fetal Growth Retardation and Postnatal Catch-Up Growth in Sheep Endocrinology, February 1, 2004; 145(2): 790 - 798. [Abstract] [Full Text] [PDF]

				T. Tukel, O. Uyguner, J. Q. Wei, M. Yuksel-Apak, N. Saka, D. X. Song, H. Kayserili, F. Bas, H. Gunoz, R. C. Wilson, et al. A Novel Semiquantitative Polymerase Chain Reaction/Enzyme Digestion-Based Method for Detection of Large Scale Deletions/Conversions of the CYP21 Gene and Mutation Screening in Turkish Families with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5893 - 5897. [Abstract] [Full Text] [PDF]

				P. W. Speiser and P. C. White Congenital Adrenal Hyperplasia N. Engl. J. Med., August 21, 2003; 349(8): 776 - 788. [Full Text] [PDF]

				Joint LWPES/ESPE CAH Working Group Consensus Statement on 21-Hydroxylase Deficiency from The Lawson Wilkins Pediatric Endocrine Society and The European Society for Paediatric Endocrinology J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4048 - 4053. [Full Text] [PDF]

				D. W. Bianchi Prenatal Exclusion of Recessively Inherited Disorders: Should Maternal Plasma Analysis Precede Invasive Techniques? Clin. Chem., May 1, 2002; 48(5): 689 - 690. [Full Text] [PDF]